Table. Medicare Fee-for-Service Expenditures for Atezolizumab for Withdrawn Indication.
| Characteristic | Outpatient Medicare Part B | ||
|---|---|---|---|
| 2018 | 2019 | 2018 and 2019 | |
| Total claims, No. | 5303 | 8879 | 14 182 |
| Urothelial cancer claims, No.a | 2383 | 2307 | 4690 |
| Second-line urothelial carcinoma claims, No.b | 635 | 606 | 1241 |
| Unique beneficiaries, No. | 116 | 76 | 157 |
| Medicare payment per claim, mean (SD), $ | 6951 (1708) | 6718 (2012) | 6854 (1843) |
| Beneficiary coinsurance per claim, mean (SD), $c | 1656 (1024) | 1821 (1657) | 1724 (1325) |
| Total payment per claim, mean (SD), $ | 8607 (2032) | 8539 (2517) | 8579 (2245) |
| Total Medicare payment, $d | 22 067 885 | 15 081 655 | 37 149 540 |
| Total beneficiary coinsurance, $ | 5 259 275 | 4 087 345 | 9346 620 |
| Total claims payment, $ | 27 327 160 | 19 169 000 | 46 496 160 |
a
Identified using Healthcare Common Procedure Coding System diagnosis codes of C65*, C66*, C67*, or C68*.
b
Second-line claims were identified if a patient used gemcitabine, pembrolizumab, or cisplatin for urothelial carcinoma before atezolizumab use.
c
Coinsurance excludes the effect of supplemental insurance and other patient offsets.
d
Total Medicare, coinsurance, and claim payments based on 20% sample results multiplied by 5 to estimate total payments for entire Medicare Fee-for-Service.